Immix Biopharma, Inc. (IMMX) Key Metrics
IMMX valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $661.6M
- Enterprise value
- $621.6M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 3.7 10-yr median 4.7
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.24
IMMX key metrics, 2019–2025
Fiscal year ended December 31, 2025 · U.S. dollarsIMMX valuation Price multiples at each fiscal year-end price.
IMMX returns How much profit the business earns on the capital it uses.
IMMX per-share figures Results divided by the shares outstanding at year-end.
IMMX financial health Debt, liquidity and how easily interest is covered.
IMMX efficiency & capital use Working capital cycle and where the cash goes.
IMMX valuation history
IMMX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
IMMX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
IMMX cash returned to shareholders
IMMX price vs earnings per share
IMMX key metrics
2019–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Valuation | |||||||
| Market capitalization | $172.4M | $62.2M | $120.0M | — | — | — | — |
| Enterprise value | $73.1M | $45.6M | $102.5M | — | — | — | — |
| Price / book | 1.8 | 4.7 | 7.3 | — | — | — | — |
| Earnings yield | −17.1% | −34.7% | −12.9% | — | — | — | — |
| Free cash flow yield | −14.3% | −25.3% | −9.5% | — | — | — | — |
| Shareholder yield (dividends + buybacks) | — | — | 0.0% | — | — | — | — |
| Share price at fiscal year-end | $5.23 | $2.20 | $6.92 | $2.29 | $3.56 | — | — |
| Per share | |||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | — | — | — | — |
| Earnings per share | −$0.89 | −$0.76 | −$0.89 | — | — | — | — |
| Operating cash flow per share | −$0.73 | −$0.52 | −$0.66 | — | — | — | — |
| Free cash flow per share | −$0.75 | −$0.56 | −$0.66 | — | — | — | — |
| Cash per share | $3.05 | $0.63 | $1.01 | — | — | — | — |
| Book value per share | $2.85 | $0.47 | $0.95 | — | — | — | — |
| Tangible book value per share | $2.85 | $0.47 | $0.95 | — | — | — | — |
| Capex per share | $0.02 | $0.04 | $0.00 | — | — | — | — |
| Debt per share | $0.03 | $0.04 | — | — | — | — | — |
| Shares outstanding | 33.0M | 28.3M | 17.3M | — | — | — | — |
| Change in shares outstanding | +16.5% | +63.1% | — | — | — | — | — |
| Returns & profitability | |||||||
| Return on equity (ROE) | −55.0% | −145.8% | −104.4% | −52.8% | −367.8% | — | — |
| Return on assets (ROA) | −46.1% | −100.8% | −88.6% | −49.7% | −260.3% | −154.9% | −103.2% |
| Return on tangible assets | −28.1% | −94.2% | −77.4% | −55.2% | −134.0% | −212.7% | −103.2% |
| Financial health | |||||||
| Total debt | $1.1M | $1.1M | — | — | $50,000 | $4.1M | $4.1M |
| Cash & short-term investments | $100.4M | $17.7M | $17.5M | $13.4M | $17.6M | $391,086 | $734,014 |
| Net debt | −$99.3M | −$16.6M | −$17.5M | −$13.4M | −$17.6M | $3.7M | $3.4M |
| Debt / equity | 0.01 | 0.08 | — | — | 0.00 | — | — |
| Debt / assets | 0.01 | 0.05 | — | — | 0.00 | 7.60 | 4.35 |
| Current ratio | 10.01 | 2.33 | 5.32 | 11.70 | 90.01 | 0.10 | 0.20 |
| Quick ratio | 10.01 | 2.33 | 5.32 | 11.70 | 90.01 | 0.10 | 0.20 |
| Interest coverage | — | — | — | — | -7.5 | -4.5 | -7.7 |
| Working capital | $91.1M | $11.5M | $16.1M | $13.6M | $18.0M | −$4.7M | −$3.7M |
| Invested capital | −$5.5M | −$3.4M | −$1.1M | −$276,909 | $395,571 | −$1.0M | −$280,372 |
| Tangible asset value | $93.8M | $13.3M | $16.2M | $13.2M | $18.0M | −$4.7M | −$3.6M |
| Net current asset value | $90.2M | $10.5M | $16.1M | $13.1M | $18.0M | −$4.7M | −$3.7M |
| Graham net-net per share | $2.71 | $0.33 | $0.85 | — | — | — | — |
| Capital allocation | |||||||
| Share buybacks (net) | — | — | $44,000 | $99,963 | $0 | — | — |
| Capex / depreciation | 2.01 | 10.21 | 9.53 | 0.00 | 0.32 | 0.00 | 6.75 |
| Efficiency | |||||||
| Days payables outstanding | 5,423.0 | 10,789.0 | 52,603.8 | 24,448.5 | 29,229.9 | 39,306.0 | 83,505.4 |
| Receivables turnover | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables turnover | 0.07 | 0.03 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | — | $1.6M | $713,944 | $140,714 | $76,579 | $151,592 | $175,748 |
| Average payables | $5.4M | $3.4M | $788,048 | $143,007 | $197,642 | $249,943 | $247,542 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from IMMX's annual financial statements (latest annual report filed March 25, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
IMMX valuation and financial ratios
Immix Biopharma earned a return on equity of −55.0% in fiscal 2025. It ended the year with $1.1 million of debt and $100.4 million in cash and short-term investments, a net cash position of $99.3 million.
See the IMMX income statement, the IMMX chart for price history, or the IMMX stock overview for the latest quote and news.
IMMX key metrics FAQ
What is Immix Biopharma's return on equity?
Immix Biopharma's return on equity (ROE) was −55.0% in fiscal 2025: net income of -$29.4 million on average shareholders' equity of $53.5 million.
How much debt does Immix Biopharma have?
Immix Biopharma had total debt of $1.1 million at the end of fiscal 2025, a debt-to-equity ratio of 0.01 and more cash than debt.
What is Immix Biopharma's free cash flow yield?
Immix Biopharma generated -$24.7 million of free cash flow in fiscal 2025, a free cash flow yield of −14.3% on its market value at year-end ($172.4 million).
What is Immix Biopharma's current ratio?
Immix Biopharma's current ratio was 10.01 at the end of fiscal 2025: current assets were 10.01 times current liabilities.